The initial published clinical reports on Medtronic PLC’s InFuse as a substitute for bone grafts in spinal fusion surgery understated the risks of the recombinant human bone morphogenetic protein-2 (rhBMP-2) relative to its benefits, according to two independent reviews of the clinical evidence published last week in the Annals of Internal Medicine.
The conclusions of the two analyses were mixed on the proper role, if any, of InFuse in spinal surgery cases going forward. Analysts suggest the data could have a nominal...